Research · head to head
DNAnexus vs Remesh
DNAnexus
Research
Regulated cloud platform for genomic and multiomic data, with GxP and FedRAMP coverage
- From
- On request
- Rated
- -
Remesh
Research
Live AI-moderated conversations with hundreds of participants at once, analysed in real time
- From
- On request
- Rated
- -
The short version
- Each has a real cost: DNAnexus no pricing is published, so an organisation cannot compare the total cost against running the same pipelines on its own cloud account until it is deep in a sales process.; Remesh pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
- They diverge on capability: DNAnexus covers Governed data storage, Remesh covers Live moderated sessions.
- Prices and features above were last checked on 31 August 2026.
Where they differ
Only the attributes on which DNAnexus and Remesh actually diverge.
Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).
What each one covers
Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.
Only in DNAnexus
- Governed data storage
- Workflow execution
- App building
- Controlled collaboration
- Compliance posture
- Cohort browsing
Only in Remesh
- Live moderated sessions
- Collective dialogue
- Flex asynchronous studies
- Video research
- Remy AI assistant
- On-Demand Recruit
- Real-time theme analysis
- Practice sessions
What people use each for
The jobs each tool is most often brought in to do.
DNAnexus
- A clinical diagnostics laboratory that needs a CLIA and CAP aligned environment for production sequencing pipelines without building the compliance evidence itselfnot Remesh
- A pharma sponsor analysing genomic endpoints in a registrational programme where 21 CFR Part 11 records are requirednot Remesh
- A biobank or consortium giving hundreds of external researchers governed access to a dataset too large to distributenot Remesh
- A diagnostics vendor packaging its pipeline as a versioned app so partner laboratories can run it without receiving the source codenot Remesh
Remesh
- A brand team that needs to test three positioning statements with 400 target customers and know by the end of the day which one lands and with whomnot DNAnexus
- An HR function running an employee listening session across several thousand staff where anonymity and volume both matternot DNAnexus
- A public affairs team needing rapid citizen consultation on a policy option with evidence of how widely each objection is heldnot DNAnexus
- An insights team that has to replace six focus groups with one session because fieldwork time has been cut and the decision cannot waitnot DNAnexus
Where each one falls short
Documented limitations, not opinions. Every one is a constraint you would hit in normal use.
DNAnexus
- No pricing is published, so an organisation cannot compare the total cost against running the same pipelines on its own cloud account until it is deep in a sales process.
- Compute and storage are billed through the platform rather than at underlying cloud list price, so the compliance envelope carries a persistent margin on every terabyte and core hour, which grows with the science rather than staying fixed.
- Data egress at genomic scale is slow and chargeable, so leaving the platform later is a real project rather than a contract decision, and that gravity weakens negotiating position at renewal.
- The regulated and validated configurations sit in a higher commercial tier than the research configuration, so an organisation that starts in research mode and later needs GxP faces a repricing rather than a setting change.
- Bioinformaticians used to running Nextflow on their own infrastructure find the platform abstractions constraining, and porting an existing pipeline into the app model is engineering work that does not carry over to any other platform.
Remesh
- Pricing is not published and third-party estimates put annual contracts in the tens of thousands of dollars, which puts it out of reach for teams that only run occasional qualitative studies and cannot commit to an annual platform fee.
- The public review picture is inconsistent in a way worth investigating: a small number of positive buyer reviews on G2 sit alongside a poor Trustpilot rating driven mostly by participant complaints, so ask directly how participants are recruited and compensated before running a study on your own customers.
- Funding has slowed sharply, from a 25 million USD round in 2021 to a 4.25 million USD round in late 2022, so procurement teams at large organisations should expect to run a vendor viability review.
- The collective dialogue mechanic rewards views that many participants recognise and vote for, which systematically under-weights genuinely novel minority insight, so it is a poor fit for exploratory discovery work where the outlier is the point.
- The discussion guide builder, especially spreadsheet import, is reported as unreliable, and because sessions are live with recruited participants a tooling failure during setup is expensive rather than merely annoying.
Pricing, plan by plan
DNAnexus
On request- DNAnexus Platform$undefined/year
- Quoted per organisation through a sales process
- Storage and compute billed through the platform rather than at cloud list price
- Regulated and validated configurations are a separate commercial tier
Remesh
On request- Remesh$undefined/year
- Live moderated sessions
- Flex asynchronous studies
- Video research
Which should you pick?
Choose DNAnexus if
- You need governed data storage.
- You work on Web, Linux.
- You also want workflow execution.
Choose Remesh if
- You need live moderated sessions.
- You work on Web, API.
- You also want collective dialogue.
Questions people ask
- Is DNAnexus or Remesh better?
- Neither clearly leads. DNAnexus starts at On request and Remesh at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
- Which is cheaper, DNAnexus or Remesh?
- DNAnexus starts at On request and Remesh at On request.
- Does DNAnexus or Remesh run on more platforms?
- DNAnexus runs on Web, Linux. Remesh runs on Web, API.
- What is DNAnexus best used for?
- DNAnexus is most often used for a clinical diagnostics laboratory that needs a clia and cap aligned environment for production sequencing pipelines without building the compliance evidence itself, a pharma sponsor analysing genomic endpoints in a registrational programme where 21 cfr part 11 records are required, a biobank or consortium giving hundreds of external researchers governed access to a dataset too large to distribute, a diagnostics vendor packaging its pipeline as a versioned app so partner laboratories can run it without receiving the source code. Of those, a clinical diagnostics laboratory that needs a clia and cap aligned environment for production sequencing pipelines without building the compliance evidence itself and a pharma sponsor analysing genomic endpoints in a registrational programme where 21 cfr part 11 records are required are not what Remesh is typically brought in for.
- What can DNAnexus do that Remesh cannot?
- DNAnexus covers Governed data storage, Workflow execution, App building, Controlled collaboration. Remesh covers Live moderated sessions, Collective dialogue, Flex asynchronous studies, Video research.
Answered from the vendors’ own pages
DNAnexus: Why pay for DNAnexus instead of raw AWS?
For the compliance evidence. GxP, FedRAMP, CLIA, CAP and Part 11 coverage removes a validation programme most organisations would otherwise have to build and maintain themselves.
Remesh: How many people can join one session?
Sessions are designed for several hundred participants at once, which is the core reason to choose it over a conventional focus group.
DNAnexus: Is validated use included?
No. Regulated and validated configurations sit in a separate commercial tier from ordinary research use.
Remesh: Does it publish pricing?
No. Contracts are quoted annually, typically scoped by session volume, and third-party estimates place them in the tens of thousands of dollars per year.
DNAnexus: Can I get my data out?
Yes, but egress at genomic scale is chargeable and slow, so plan exit costs at the point of signing.
Remesh: Can it replace a survey?
Not entirely. It produces open-ended language with agreement percentages, which is stronger than a survey for understanding reasoning but weaker for precise population estimates.
DNAnexus: Does it host UK Biobank?
Yes, DNAnexus hosts the UK Biobank research analysis platform, which has its own access approval and cost terms.
Remesh: Does Remesh recruit participants for me?
Yes, through On-Demand Recruit, typically delivering a panel within about 24 hours, or you can bring your own list.
Related pages
Other head to heads
- DNAnexus vs Benchling
- DNAnexus vs Terra
- DNAnexus vs Seven Bridges
- DNAnexus vs Form Bio
- DNAnexus vs Labguru
- DNAnexus vs Dotmatics
- DNAnexus vs TetraScience
- DNAnexus vs Schrodinger
- DNAnexus vs LabWare
- DNAnexus vs STARLIMS
- DNAnexus vs Castor EDC
- DNAnexus vs Condens
- DNAnexus vs SurveySparrow
- DNAnexus vs Contentsquare
- DNAnexus vs LabArchives
- DNAnexus vs NVivo
- DNAnexus vs GWI
- DNAnexus vs Aurelius
- DNAnexus vs Dovetail
- DNAnexus vs Suzy
- DNAnexus vs SurveyMonkey
- DNAnexus vs Zappi
- DNAnexus vs Greenphire
- DNAnexus vs Marvin
- DNAnexus vs Chemaxon
- Remesh vs Benchling
- Remesh vs Terra
- Remesh vs Seven Bridges
- Remesh vs Form Bio
- Remesh vs Labguru
- Remesh vs Dotmatics
- Remesh vs TetraScience
- Remesh vs Schrodinger
- Remesh vs LabWare
- Remesh vs STARLIMS
- Remesh vs Castor EDC
- Remesh vs Condens
- Remesh vs SurveySparrow
- Remesh vs Contentsquare
- Remesh vs LabArchives
- Remesh vs NVivo
- Remesh vs GWI
- Remesh vs Aurelius
- Remesh vs Dovetail
- Remesh vs Suzy
- Remesh vs SurveyMonkey
- Remesh vs Zappi
- Remesh vs Greenphire
- Remesh vs Marvin
- Remesh vs Chemaxon